At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Phase II Trial of Bortezomib (Velcade), Melphalan, and Dexamethasone (V-MD) in Patients With Symptomatic AL-Amyloidosis or Light Chain Deposition Disease
In Brief
A Phase 2 clinical trial evaluating bortezomib, dexamethasone, and 5 other interventions for Primary Systemic Amyloidosis and Light Chain Deposition Disease. Completed, enrolled 35 participants across 7 sites.
Detailed Summary
RATIONALE: Giving bortezomib together with melphalan and dexamethasone may be an effective treatment for primary amyloidosis and light chain deposition disease. PURPOSE: This phase II trial is studying how well giving bortezomib together with melphalan and dexamethasone works in treating patients with primary amyloidosis or light chain deposition disease.
Study Details
Timeline
Interventions
Bortezomib 1.3 mg/m2 days 1, 8, 15, 22
Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23
Melphalan 9 mg/m2/day days 1-4
≤28 days prior to enrollment
Day 1 of cycles 6, 12, 18 and at end of study.
≤28 days prior to enrollment
Start of each cycle